Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer

Journal of Clinical Oncology

Volumn 27, Issue 15, 2009, Pages 2436-2442

  Morris, Michael J ^a   Pandit Taskar, Neeta ^a   Carrasquillo, Jorge ^a   Divgi, Chaitanya R ^a   Slovin, Susan ^a   Kelly, William K ^a   Rathkopf, Dana ^a   Gignac, Gretchen A ^a   Solit, David ^a   Schwartz, Lawrence ^a   Stephenson, Ryan D ^a   Hong, Christina ^a   Delacruz, Anthony ^a   Curley, Tracy ^a   Heller, Glenn ^a   Jia, Xiaoyu ^a   O'Donoghue, Joseph ^a   Larson, Steven ^a   Scher, Howard I ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; LEXIDRONAM SAMARIUM SM 153; PROSTATE SPECIFIC ANTIGEN; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE; TAXOID;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CLOTTING DISORDER; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; ADENOCARCINOMA; BLOOD; BONE; BONE TUMOR; DRUG RESISTANCE; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, NON-NARCOTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE AND BONES; BONE NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TAXOIDS;

EID: 66349100456     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.4164     Document Type: Article

References (11)

1. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004 (Pubitemid 39315318)
2. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004 (Pubitemid 39315317)
3. Tu SM, Millikan RE, Mengistu B, et al: Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet 357:336-341, 2001 (Pubitemid 32128538)
4. Higano CS, Quick DP, Bushnell D, et al: Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone. Clin Genitourin Cancer 6:40-45, 2008 (Pubitemid 351656243)
5. Sartor O, Reid RH, Bushnell DL, et al: Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 109:637-643, 2007 (Pubitemid 46190974)
6. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
7. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008
8. Kallen A: Computational Pharmacokinetics. Boca Raton, FL, Chapman and Hall, 2008
9. Jung K, Lein M, Stephan C, et al: Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications. Int J Cancer 111:783-791, 2004 (Pubitemid 39062904)
10. Cook RJ, Coleman R, Brown J, et al: Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 12:3361-3367, 2006 (Pubitemid 43910880)
11. Coleman RE, Major P, Lipton A, et al: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925-4935, 2005 (Pubitemid 46223998)